Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Conditions
Keywords
recurrent adult Hodgkin lymphoma
Brief summary
RATIONALE: HIV protease inhibitors, including Lopinavir/Ritonavir have intrinsic anti-apoptotic properties in addition to their anti-viral effect on HIV. This anti-apoptotic effect may boost the immune system to help the body create a better immune response to vaccines. PURPOSE: This randomized clinical trial studies giving lopinavir and ritonavir together in improving immune response to vaccines in patients with complete remission following a bone marrow transplant for Hodgkin lymphoma.
Detailed description
PRIMARY OBJECTIVES: I. Compare TREC positive recent thymic emigrants, and naive CD4+ and CD8+ T cell numbers between treatment groups. SECONDARY OBJECTIVES: I. Compare post-vaccination anti-rabies antibody titers between treatment groups. II. Compare post-vaccination cytokine levels, including IL1, IL2, IL4, IL6, IL7, IL8, IL10, IL12, INFgamma, TNFalpha, between treatment groups. III. Compare post-vaccination anti-rabies ELISPOT reaction between treatment groups. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive oral lopinavir and oral ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive no therapy. All patients then receive a neo-antigen rabies vaccine.
Interventions
DRUGlopinavir
Given orally
DRUGritonavir
Given orally
GENETICpolymerase chain reaction
Correlative studies
OTHERflow cytometry
Correlative studies
OTHERenzyme-linked immunosorbent assay
Correlative studies
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult subjects who are in complete remission at Day +100 after a bone marrow transplant for Hodgkins Lymphoma * Normal AST or ALT, serum creatinine and 12-lead electrocardiogram within the previous 6 months * Females of childbearing potential must have negative beta-HCG (urine or plasma) within the last month and agree to effective contraception during the course of the study * Willingness and ability to give informed consent * Willingness and ability to take pills twice a day for 28 days
Exclusion criteria
* Known HIV positive * Screening ALT or AST greater than 3X upper limit of normal * Baseline QTc greater than 500 msec * Current treatment with immunosuppressive agent (systemic glucocorticoid, cyclosporine, mycophenolate, azathioprine, sirolimus, Rituximab, infliximab, adalimumab) * Current treatment with any of the following: cisapride, ergot derivatives, amiodarone, quinidine, terfenadine, astemizole, rifampin/rifabutin, carbamazepine, phenobarbital, sildenafil, St. John's wort, azithromycin, carbamazepine, HIV anti-virals, methadone, pimozide, phenytoin, sedative hypnotics (midazolam, triazolam), HMG-CoA reductase inhibitors (lovastatin, simvastatin, atorvastatin) * Active malignancy requiring chemotherapy or radiation * Baseline creatinine of \> 2.0 * Active infection requiring systemic anti-infective agent (excluding prophylactic antibiotics) * Hypersensitivity to processed bovine gelatin, chicken protein, neomycin, amphotericin B or chlortetracycline * Subject must not be on medications that interact with the metabolism of protease inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of TREC positive recent thymic emigrants, and naive CD4+ and CD8+ T cell numbers between treatment groups | 90 days |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of post-vaccination anti-rabies antibody titers between treatment groups | 90 days |
| Comparison of post-vaccination cytokine levels, including IL1, IL2, IL4, IL6, IL7, IL8, IL10, IL12, INFgamma, TNFalpha, between treatment groups | 90 days |
| Comparison of post-vaccination anti-rabies ELISPOT reaction between treatment groups | 90 days |
Countries
United States
Outcome results
None listed